메뉴 건너뛰기




Volumn 4, Issue 3, 2015, Pages 170-196

Opportunities for conformation-selective antibodies in amyloid-related diseases

Author keywords

Alzheimer s; Amyloids; Antibody; Conformation; Fibrils; Huntingtin; Parkinson s; Prion; Protein misfolding; Tau

Indexed keywords

A 887755; ADUCANUMAB; ALPHA SYNUCLEIN; ALZHEIMER DISEASE VACCINE; AMY 33; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; ANTIBODY; BAN 2401; BAPINEUZUMAB; CRENEZUMAB; EPITOPE; GANTENERUMAB; HUNTINGTIN; KW 1; MONOCLONAL ANTIBODY; PRESENILIN; PRION PROTEIN; PRION PROTEIN ANTIBODY; SAR 228810; SOLANEZUMAB; TAU PROTEIN; TAU PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

EID: 84989958173     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib4030170     Document Type: Review
Times cited : (7)

References (133)
  • 1
    • 0842281551 scopus 로고    scopus 로고
    • Principles of protein folding, misfolding and aggregation
    • Dobson, C. Principles of protein folding, misfolding and aggregation. Semin. Cell Develop. Biol. 2004, 15, 3-16.
    • (2004) Semin. Cell Develop. Biol. , vol.15 , pp. 3-16
    • Dobson, C.1
  • 2
    • 84892408458 scopus 로고    scopus 로고
    • Mechanisms of protein-folding diseases at a glance
    • Valastyan, J.S.; Lindquist, S. Mechanisms of protein-folding diseases at a glance. Dis. Model. Mechan. 2014, 7, 9-14.
    • (2014) Dis. Model. Mechan. , vol.7 , pp. 9-14
    • Valastyan, J.S.1    Lindquist, S.2
  • 3
    • 46749117136 scopus 로고    scopus 로고
    • Molecular and cellular aspects of protein misfolding and disease
    • Herczenik, E.; Gebbink, M.F.B.G. Molecular and cellular aspects of protein misfolding and disease. FASEB J. 2008, 22, 2115-2133.
    • (2008) FASEB J. , vol.22 , pp. 2115-2133
    • Herczenik, E.1    Gebbink, M.F.B.G.2
  • 5
    • 0037135111 scopus 로고    scopus 로고
    • The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
    • Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
    • (2002) Science , vol.297 , pp. 353-356
    • Hardy, J.1    Selkoe, D.J.2
  • 6
    • 70349705441 scopus 로고    scopus 로고
    • Prions: Protein aggregation and infectious diseases
    • Aguzzi, A.; Calela, A.M. Prions: Protein aggregation and infectious diseases. Physiol. Rev. 2009, 89, 1105-1152.
    • (2009) Physiol. Rev. , vol.89 , pp. 1105-1152
    • Aguzzi, A.1    Calela, A.M.2
  • 7
    • 77649202326 scopus 로고    scopus 로고
    • Protein aggregation diseases: Pathogenicity and therapeutic perspectives
    • Aguzzi, A.; O'Connor, T. Protein aggregation diseases: Pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov. 2010, 9, 237-248.
    • (2010) Nat. Rev. Drug Discov. , vol.9 , pp. 237-248
    • Aguzzi, A.1    O'Connor, T.2
  • 8
    • 84871414210 scopus 로고    scopus 로고
    • The many faces of α-synuclein: From structure and toxicity to therapeutic target
    • Lashuel, H.A.; Overk, C.R.; Oueslati, A.; Masliah, E. The many faces of α-synuclein: From structure and toxicity to therapeutic target. Nature 2013, 14, 38-42.
    • (2013) Nature , vol.14 , pp. 38-42
    • Lashuel, H.A.1    Overk, C.R.2    Oueslati, A.3    Masliah, E.4
  • 9
    • 83455202793 scopus 로고    scopus 로고
    • α-Synuclein misfolding and Parkinson's disease
    • Breydo, L.; Wu, J.W.; Uversky, V.N. α-Synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta 2012, 1822, 261-285.
    • (2012) Biochim. Biophys. Acta , vol.1822 , pp. 261-285
    • Breydo, L.1    Wu, J.W.2    Uversky, V.N.3
  • 10
    • 84880730823 scopus 로고    scopus 로고
    • Huntington's disease: Underlying molecular mechanisms and emerging concepts
    • Labbadia, J.; Morimoto, R.I. Huntington's disease: Underlying molecular mechanisms and emerging concepts. Trends Biochem. Sci. 2013, 38, 378-385.
    • (2013) Trends Biochem. Sci. , vol.38 , pp. 378-385
    • Labbadia, J.1    Morimoto, R.I.2
  • 11
    • 84957935046 scopus 로고    scopus 로고
    • Alzheimer's association. (accessed on 28 December 2014)
    • Alzheimer's association. Alzheimer's Disease and Dementia. Available online: http://www.alz.org (accessed on 28 December 2014).
    • Alzheimer's Disease and Dementia.
  • 12
    • 27844445619 scopus 로고    scopus 로고
    • Acetylcholinasterase inhibitors for the treatment of dementia in Alzheimer's disease: Do we need ne inhibitors?
    • Small, D.H. Acetylcholinasterase inhibitors for the treatment of dementia in Alzheimer's disease: Do we need ne inhibitors? Exp. Opin. Emerg. Drugs 2005, 10, 817-825.
    • (2005) Exp. Opin. Emerg. Drugs , vol.10 , pp. 817-825
    • Small, D.H.1
  • 13
    • 68649126582 scopus 로고    scopus 로고
    • Targets for neuroprotection in Parkinson's disease
    • Yacoubian, T.A.; Standaert, D.G. Targets for neuroprotection in Parkinson's disease. Biochim. Biophys. Acta 2009, 1792, 676-687.
    • (2009) Biochim. Biophys. Acta , vol.1792 , pp. 676-687
    • Yacoubian, T.A.1    Standaert, D.G.2
  • 15
    • 84858374665 scopus 로고    scopus 로고
    • The amyloid state of proteins in human diseases
    • Eisenberg, D.; Jucker, M. The amyloid state of proteins in human diseases. Cell 2012, 148, 1188-1203.
    • (2012) Cell , vol.148 , pp. 1188-1203
    • Eisenberg, D.1    Jucker, M.2
  • 17
    • 33847662852 scopus 로고    scopus 로고
    • Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid s-peptide
    • Haas, C.; Selkoe, D.J. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid s-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8, 101-112.
    • (2007) Nat. Rev. Mol. Cell Biol. , vol.8 , pp. 101-112
    • Haas, C.1    Selkoe, D.J.2
  • 18
    • 84877254025 scopus 로고    scopus 로고
    • Possitive anti-amyloid immunotheraphy in Alzheimer's disease: What are the most promising targets?
    • Moreth, J.; Mavoungou, C.; Schindowski, K. Possitive anti-amyloid immunotheraphy in Alzheimer's disease: What are the most promising targets? Immun. Ageing 2013, 10, 18-27.
    • (2013) Immun. Ageing , vol.10 , pp. 18-27
    • Moreth, J.1    Mavoungou, C.2    Schindowski, K.3
  • 19
    • 84857642949 scopus 로고    scopus 로고
    • The toxic A11oligomer and Alzheimer's disease: An emperor in need of clothes
    • Benilova, I.; Karran, E.; De Strooper, B. The toxic A11oligomer and Alzheimer's disease: An emperor in need of clothes. Nat. Neurosci. 2012, 15, 349-357.
    • (2012) Nat. Neurosci. , vol.15 , pp. 349-357
    • Benilova, I.1    Karran, E.2    De Strooper, B.3
  • 20
    • 36749078121 scopus 로고    scopus 로고
    • Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers
    • Kayed, R.; Head, E.; Sarsoza, F.; Saing, T.; Cotman, C.W.; Necula, M.; Margol, L.; Wu, J.; Breydo, L.; Thompson, J.L.; et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegen. 2007, 2, 18-29.
    • (2007) Mol. Neurodegen. , vol.2 , pp. 18-29
    • Kayed, R.1    Head, E.2    Sarsoza, F.3    Saing, T.4    Cotman, C.W.5    Necula, M.6    Margol, L.7    Wu, J.8    Breydo, L.9    Thompson, J.L.10
  • 25
    • 0030058382 scopus 로고
    • Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer 83-amyloid peptide
    • Salomon, B.; Koppel, R.; Hanan, E.; Katzav, T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer 83-amyloid peptide. Proc. Natl. Acad. Sci. USA 1995, 93, 452-455.
    • (1995) Proc. Natl. Acad. Sci. USA , vol.93 , pp. 452-455
    • Salomon, B.1    Koppel, R.2    Hanan, E.3    Katzav, T.4
  • 26
    • 84858720343 scopus 로고    scopus 로고
    • Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease
    • Weggen, S.; Beher, D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimers Res. Ther. 2012, 4, 9.
    • (2012) Alzheimers Res. Ther , vol.4 , pp. 9
    • Weggen, S.1    Beher, D.2
  • 28
    • 0030005625 scopus 로고    scopus 로고
    • Tau protein and the neurofibrillary pathology of Alzheimer's disease
    • Goedert, M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Ann. NY Acad. Sci. 1996, 777, 121-131.
    • (1996) Ann. NY Acad. Sci. , vol.777 , pp. 121-131
    • Goedert, M.1
  • 29
    • 13844275951 scopus 로고    scopus 로고
    • Mean age of onset in familial Alzheimer's disease is determined by amyloid beta42
    • Duering, M.; Grimm, M.O.; Grimm, H.S.; Schroder, J.; Hartmann, T. Mean age of onset in familial Alzheimer's disease is determined by amyloid beta42. Neurobiol. Aging 2005, 26,785-788.
    • (2005) Neurobiol. Aging , vol.26 , pp. 785-788
    • Duering, M.1    Grimm, M.O.2    Grimm, H.S.3    Schroder, J.4    Hartmann, T.5
  • 30
    • 78149488153 scopus 로고    scopus 로고
    • Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis
    • Pimplikar, S.W.; Nixon, R.A.; Robakis, N.K.; Shen, J.; Tsai, L. Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis. J. Neurosci. 2010, 30, 14946-14954.
    • (2010) J. Neurosci. , vol.30 , pp. 14946-14954
    • Pimplikar, S.W.1    Nixon, R.A.2    Robakis, N.K.3    Shen, J.4    Tsai, L.5
  • 32
    • 0037393454 scopus 로고    scopus 로고
    • Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report
    • Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P., Markham, H.; Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report. Nat. Med. 2003, 9, 448-452.
    • (2003) Nat. Med. , vol.9 , pp. 448-452
    • Nicoll, J.A.1    Wilkinson, D.2    Holmes, C.3    Steart, P.4    Markham, H.5    Weller, R.O.6
  • 34
    • 84874330804 scopus 로고    scopus 로고
    • Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
    • Miles, L.A.; Crespi, G.A.N.; Doughty, L.; Parker, M.W. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Nat. Sci. Rep. 2013, 3, 1303.
    • (2013) Nat. Sci. Rep. , vol.3 , pp. 1303
    • Miles, L.A.1    Crespi, G.A.N.2    Doughty, L.3    Parker, M.W.4
  • 39
    • 85117465579 scopus 로고    scopus 로고
    • End of the RoAD for Gantenerumab? (accessed on 27 June 2015)
    • End of the RoAD for Gantenerumab? Roche Declares Prodromal Alzheimer's Trial Futile. Available online: http://www.alzforum.org/news/research-news/end-road-gantenerumab-rochedeclares- prodromal-alzheimers-trial-futile (accessed on 27 June 2015).
    • Roche Declares Prodromal Alzheimer's Trial Futile.
  • 40
    • 84886937126 scopus 로고    scopus 로고
    • Immunotherapy for Alzheimer's disease: Hoops and hurdles
    • Lemere, C.A. Immunotherapy for Alzheimer's disease: Hoops and hurdles. Mol. Neurodegener. 2013, 8, 36-42.
    • (2013) Mol. Neurodegener. , vol.8 , pp. 36-42
    • Lemere, C.A.1
  • 42
    • 75849124774 scopus 로고    scopus 로고
    • (accessed on 27 June 2015)
    • Clinical Trials. Available online: www.clinicalcrials.gov (accessed on 27 June 2015).
    • Clinical Trials.
  • 44
    • 0038117796 scopus 로고    scopus 로고
    • Correlation between elevated levels if amyloid C-peptide in the brain and cognitive decline
    • Naslund, J.; Haroutunian, V.; Mohs, R.; Davis, K.L.; Davis, P.; Greengard, P.; Buxbaum, J. Correlation between elevated levels if amyloid C-peptide in the brain and cognitive decline. JAMA 2000, 283, 1571-1577.
    • (2000) JAMA , vol.283 , pp. 1571-1577
    • Naslund, J.1    Haroutunian, V.2    Mohs, R.3    Davis, K.L.4    Davis, P.5    Greengard, P.6    Buxbaum, J.7
  • 45
    • 0026756887 scopus 로고
    • Methological variables in the assessment of 4-amyloid neurotoxicity
    • Busciglio, J.; Lorenzo, A.; Yankner, B. Methological variables in the assessment of 4-amyloid neurotoxicity. Neurobiol. Aging 1992, 13, 609-612.
    • (1992) Neurobiol. Aging , vol.13 , pp. 609-612
    • Busciglio, J.1    Lorenzo, A.2    Yankner, B.3
  • 46
    • 84858984601 scopus 로고    scopus 로고
    • Unravelling the early events of amyloid-44Protein (Ar) aggregation: Techniques for the determination of Aaaaggregate size
    • Pryor, N.E.; Moss, M.A.; Hestekin, C.N. Unravelling the early events of amyloid-44Protein (Ar) aggregation: Techniques for the determination of Aaaaggregate size. Int. J. Mol. Sci. 2012, 13, 3038-3072.
    • (2012) Int. J. Mol. Sci. , vol.13 , pp. 3038-3072
    • Pryor, N.E.1    Moss, M.A.2    Hestekin, C.N.3
  • 47
    • 79951761390 scopus 로고    scopus 로고
    • The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: Oligomer size or conformation?
    • Broersen, K.; Rousseau, F.; Schymkowitz, J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Alzheimer's Res. Ther. 2010, 2, 12.
    • (2010) Alzheimer's Res. Ther. , vol.2 , pp. 12
    • Broersen, K.1    Rousseau, F.2    Schymkowitz, J.3
  • 48
    • 57649148788 scopus 로고    scopus 로고
    • Structural classification of toxic amyloid oligomers
    • Glabe, C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 2008, 283, 29639-29643.
    • (2008) J. Biol. Chem. , vol.283 , pp. 29639-29643
    • Glabe, C.G.1
  • 49
    • 79251567055 scopus 로고    scopus 로고
    • Crystal structure of the amyloid-βp3 fragment provides a model for oligomer formation in Alzheimer's disease
    • Streltsov, V.A.; Varghese, J.N.; Masters, C.L.; Nuttall, S.D. Crystal structure of the amyloid-βp3 fragment provides a model for oligomer formation in Alzheimer's disease. J. Neurosci. 2011, 31, 1419-1426.
    • (2011) J. Neurosci. , vol.31 , pp. 1419-1426
    • Streltsov, V.A.1    Varghese, J.N.2    Masters, C.L.3    Nuttall, S.D.4
  • 50
    • 56249092747 scopus 로고    scopus 로고
    • Anti-oligomeric Aβ single chain variable domain antibody blocks Aβ-induced toxicity against human neuroblastoma cells
    • Zameer, A.; Kasturirangan, S.; Emadi, S.; Nimmagadda, S.V.; Sierks, M.R. Anti-oligomeric Aβ single chain variable domain antibody blocks Aβ-induced toxicity against human neuroblastoma cells. J. Mol. Biol. 2008, 384, 917-928.
    • (2008) J. Mol. Biol. , vol.384 , pp. 917-928
    • Zameer, A.1    Kasturirangan, S.2    Emadi, S.3    Nimmagadda, S.V.4    Sierks, M.R.5
  • 51
    • 58249104047 scopus 로고    scopus 로고
    • Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formation
    • Lafaye, P.; Achour, I.; England, P.; Duyckaerts, C.; Rougeon, F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formation. Mol. Immunol. 2009, 46, 695-704.
    • (2009) Mol. Immunol. , vol.46 , pp. 695-704
    • Lafaye, P.1    Achour, I.2    England, P.3    Duyckaerts, C.4    Rougeon, F.5
  • 53
  • 56
    • 84879025530 scopus 로고    scopus 로고
    • Restoration of home cage activity in Tg2576 mice by immunotherapy with the Ab-oligomer selective antibody A-887755
    • Relo, A.; Barghorn, S.; Ebert, U.; Hillen, H.; Gross, G.; Schoemaker, H.; Bespalov, A. Restoration of home cage activity in Tg2576 mice by immunotherapy with the Ab-oligomer selective antibody A-887755. Alzheimer's Dement. 2011, 7, S772.
    • (2011) Alzheimer's Dement. , vol.7
    • Relo, A.1    Barghorn, S.2    Ebert, U.3    Hillen, H.4    Gross, G.5    Schoemaker, H.6    Bespalov, A.7
  • 57
    • 84989182917 scopus 로고    scopus 로고
    • Perspectives on future Alzheimer's therapies: Amyloid-ssprotofibrils-a new target for immunotherapy with BAN2401 in Alzheimer's disease
    • Lannfelt, L.; Moller, C.; Basun, H.; Osswald, G.; Sehlin, D.; Satlin, A.; Logovinsky, V.; Gellerfors, P. Perspectives on future Alzheimer's therapies: amyloid-ssprotofibrils-a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimer's Res. Ther. 2014, 6, 16-24.
    • (2014) Alzheimer's Res. Ther. , vol.6 , pp. 16-24
    • Lannfelt, L.1    Moller, C.2    Basun, H.3    Osswald, G.4    Sehlin, D.5    Satlin, A.6    Logovinsky, V.7    Gellerfors, P.8
  • 58
    • 62049083728 scopus 로고    scopus 로고
    • Directin vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers
    • Meli, G.; Visintin, M.; Cannistraci, I.; Cattaneo, A. Directin vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. J. Mol. Biol. 2009, 387, 584-606.
    • (2009) J. Mol. Biol. , vol.387 , pp. 584-606
    • Meli, G.1    Visintin, M.2    Cannistraci, I.3    Cattaneo, A.4
  • 59
    • 84901502442 scopus 로고    scopus 로고
    • Conformational targeting of intracellular ACColigomers demonstrates their pathological oligomerization inside the endoplasmic reticulum
    • Meli, G.; Lecci, A.; Manca, A.; Krako, N.; Albertini, V.; Benussi, L.; Ghidoni, R.; Cattaneo, A. Conformational targeting of intracellular ACColigomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. Nat. Commun. 2014, 3, 3867-3878.
    • (2014) Nat. Commun. , vol.3 , pp. 3867-3878
    • Meli, G.1    Lecci, A.2    Manca, A.3    Krako, N.4    Albertini, V.5    Benussi, L.6    Ghidoni, R.7    Cattaneo, A.8
  • 62
    • 84894366258 scopus 로고    scopus 로고
    • P.; Tortelli, R.; Santamato, A.; Logroscino, G.; Amyloidbased immunotherapy for Alzheimer's disease in the time of prevention trials: The way forward
    • Panza, F; Solfrizzi, V.; Imbimbo, B. P.; Tortelli, R.; Santamato, A.; Logroscino, G.; Amyloidbased immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev. Clin. Immunol. 2014, 10, 405-419.
    • (2014) Expert Rev. Clin. Immunol. , vol.10 , pp. 405-419
    • Panza, F.1    Solfrizzi, V.2    Imbimbo, B.3
  • 64
    • 84885649629 scopus 로고    scopus 로고
    • Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: End of beginning or beginning of end?
    • Li, Y.; Liu, Y.; Wang, Z.; Jiang, Y. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end? Expert Rev. Clin. Immunol. 2013, 13, 1515-1522.
    • (2013) Expert Rev. Clin. Immunol. , vol.13 , pp. 1515-1522
    • Li, Y.1    Liu, Y.2    Wang, Z.3    Jiang, Y.4
  • 65
    • 0036085702 scopus 로고    scopus 로고
    • Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals
    • Weksler, M.E.; Relkin, N.; Turkenich, R.; LaRusse, S.; Zhou, L.; Szabo, P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 2002, 37, 943-948.
    • (2002) Exp. Gerontol. , vol.37 , pp. 943-948
    • Weksler, M.E.1    Relkin, N.2    Turkenich, R.3    LaRusse, S.4    Zhou, L.5    Szabo, P.6
  • 66
    • 68949169046 scopus 로고    scopus 로고
    • IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders
    • Fillit, H.; Hess, G.; Hill, J.; Bonnet, P.; Toso, C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009, 73, 180-185.
    • (2009) Neurology , vol.73 , pp. 180-185
    • Fillit, H.1    Hess, G.2    Hill, J.3    Bonnet, P.4    Toso, C.5
  • 68
    • 84881340502 scopus 로고    scopus 로고
    • Naturally occurring autoantibodies interfere with [beta]-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer/'s disease 24h after single treatment
    • Mengel, D.; Roskam, S.; Neff, F.; Balakrishnan, K.; Deuster, O.; Gold, M.; Oertel, W.H.; Bacher, M.; Bach, J.-P.; Dodel, R. Naturally occurring autoantibodies interfere with [beta]-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer/'s disease 24h after single treatment. Transl. Psychiat. 2013, 3, 233-243.
    • (2013) Transl. Psychiat. , vol.3 , pp. 233-243
    • Mengel, D.1    Roskam, S.2    Neff, F.3    Balakrishnan, K.4    Deuster, O.5    Gold, M.6    Oertel, W.H.7    Bacher, M.8    Bach, J.-P.9    Dodel, R.10
  • 69
    • 79955758133 scopus 로고    scopus 로고
    • Naturally occurring autoantibodies against beta-amyloid: Investigating their role in transgenic animal and in vitro models of Alzheimer's disease
    • Dodel, R.; Balakrishnan, K.; Keyvani, K.; Deuster, O.; Neff, F.; Andrei-Selmer, L.C.; Roskam, S.; Stuer, C.; Al-Abed, Y.; Noelker, C.; et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J. Neurosci. 2011, 31, 5847-5854.
    • (2011) J. Neurosci. , vol.31 , pp. 5847-5854
    • Dodel, R.1    Balakrishnan, K.2    Keyvani, K.3    Deuster, O.4    Neff, F.5    Andrei-Selmer, L.C.6    Roskam, S.7    Stuer, C.8    Al-Abed, Y.9    Noelker, C.10
  • 70
    • 0027361281 scopus 로고
    • Microtubule associated protein tau: Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease
    • Kfpke, E.; Tung, Y.C.; Shaikh, S.; Alonso, A.C.; Iqbal, K.; Grundke-Iqbal, I. Microtubule associated protein tau: abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 1993, 268, 24374-24384.
    • (1993) J. Biol. Chem. , vol.268 , pp. 24374-24384
    • Kfpke, E.1    Tung, Y.C.2    Shaikh, S.3    Alonso, A.C.4    Iqbal, K.5    Grundke-Iqbal, I.6
  • 71
    • 0036937699 scopus 로고    scopus 로고
    • Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease
    • Augustinack, J.C.; Schneider, A.; Mandelkow, E.M.; Hyman, B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002, 103, 26-35.
    • (2002) Acta Neuropathol. , vol.103 , pp. 26-35
    • Augustinack, J.C.1    Schneider, A.2    Mandelkow, E.M.3    Hyman, B.T.4
  • 73
    • 54249156984 scopus 로고    scopus 로고
    • Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies
    • Sigurdsson, E.M. Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies. J. Alzheimers Dis. 2008, 15, 157-168.
    • (2008) J. Alzheimers Dis , vol.15 , pp. 157-168
    • Sigurdsson, E.M.1
  • 74
    • 84865607168 scopus 로고    scopus 로고
    • Mechanistic studies of antibody-mediated clearance of Tau aggregates using an ex vivo brain slice model
    • Krishnamurthy, P.K.; Deng, Y.; Sigurdsson, E.M. Mechanistic studies of antibody-mediated clearance of Tau aggregates using an ex vivo brain slice model. Front. Psychiat. 2011, 2, 59.
    • (2011) Front. Psychiat. , vol.2 , pp. 59
    • Krishnamurthy, P.K.1    Deng, Y.2    Sigurdsson, E.M.3
  • 75
    • 84887837879 scopus 로고    scopus 로고
    • Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology
    • Gu, J.; Congdon, E.E.; Sigurdsson, E.M. Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology. J. Biol. Chem. 2013, 288, 33081-33091.
    • (2013) J. Biol. Chem. , vol.288 , pp. 33081-33091
    • Gu, J.1    Congdon, E.E.2    Sigurdsson, E.M.3
  • 76
    • 84890282160 scopus 로고    scopus 로고
    • Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fc_ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance
    • Congdon, E.E.; Gu, J.; Sait, H.B.R.; Sigurdsson, E.M. Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fc_ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance. J. Biol. Chem. 2013, 288, 35452-35465.
    • (2013) J. Biol. Chem. , vol.288 , pp. 35452-35465
    • Congdon, E.E.1    Gu, J.2    Sait, H.B.R.3    Sigurdsson, E.M.4
  • 77
    • 84927662307 scopus 로고    scopus 로고
    • Tau-based therapeutic approaches for Alzheimer's disease- A mini-review
    • Boutajangout, A.; Wisniewski, T. Tau-based therapeutic approaches for Alzheimer's disease- A mini-review. Gerontology 2014, 60, 381-385.
    • (2014) Gerontology , vol.60 , pp. 381-385
    • Boutajangout, A.1    Wisniewski, T.2
  • 78
    • 80855148339 scopus 로고    scopus 로고
    • Opposing roles of microglial activation in amyloid depositing and tau depositing transgenic mice
    • Morgan, D.; Lee, D.; Brownlow, M.; Selenica, M.-L.; Reid, P.; Alvarez, J.; Gordon, M.N. Opposing roles of microglial activation in amyloid depositing and tau depositing transgenic mice. Neurodegen. Dis. 2011, 8 (Suppl. 1), 1.
    • (2011) Neurodegen. Dis. , vol.8 , pp. 1
    • Morgan, D.1    Lee, D.2    Brownlow, M.3    Selenica, M.-L.4    Reid, P.5    Alvarez, J.6    Gordon, M.N.7
  • 79
    • 84876908676 scopus 로고    scopus 로고
    • Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity
    • d'Abramo, C.; Acker, C.M.; Jimenez, H.T.; Davies, P. Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity. PLoS One 2013, 8, e62402.
    • (2013) PLoS One , vol.8
    • d'Abramo, C.1    Acker, C.M.2    Jimenez, H.T.3    Davies, P.4
  • 80
    • 67649273927 scopus 로고    scopus 로고
    • Propagation of Tau Misfolding from the Outside to the Inside of a Cell
    • Frost, B.; Jacks, R.L.; Diamond, M.I. Propagation of Tau Misfolding from the Outside to the Inside of a Cell. J. Biol. Chem. 2009, 284, 12845-12852.
    • (2009) J. Biol. Chem. , vol.284 , pp. 12845-12852
    • Frost, B.1    Jacks, R.L.2    Diamond, M.I.3
  • 81
    • 79955441814 scopus 로고    scopus 로고
    • Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles
    • Guo, J.L.; Lee, V.M. Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles. J. Biol. Chem. 2011, 286, 15317-15331.
    • (2011) J. Biol. Chem. , vol.286 , pp. 15317-15331
    • Guo, J.L.1    Lee, V.M.2
  • 84
    • 84861758226 scopus 로고    scopus 로고
    • Trans-cellular propagation of Tau aggregation by fibrillar species
    • Kfoury, N.; Holmes, B.B.; Jiang, H.; Holtzman, D.M.; Diamond, M.I. Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 2012, 287, 19440-19451.
    • (2012) J. Biol. Chem. , vol.287 , pp. 19440-19451
    • Kfoury, N.1    Holmes, B.B.2    Jiang, H.3    Holtzman, D.M.4    Diamond, M.I.5
  • 86
    • 84877580799 scopus 로고    scopus 로고
    • Immunotherapy for neurodegenerative diseases: Focus on 8-synucleinopathies
    • Valera, E.; Masliah, E. Immunotherapy for neurodegenerative diseases: Focus on 8-synucleinopathies. Pharmacol. Therap. 2013, 138, 311-322.
    • (2013) Pharmacol. Therap. , vol.138 , pp. 311-322
    • Valera, E.1    Masliah, E.2
  • 87
    • 0025863618 scopus 로고
    • Neuropathological stageing of Alzheimer-related changes
    • Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239-259.
    • (1991) Acta Neuropathol. , vol.82 , pp. 239-259
    • Braak, H.1    Braak, E.2
  • 94
    • 84862609075 scopus 로고    scopus 로고
    • Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice
    • Luk, K.C.; Kehm, V.M.; Zhang, B.; O'Brien, P.; Trojanowski, J.Q.; Lee, V.M. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 2012, 209, 975-986.
    • (2012) J. Exp. Med , vol.209 , pp. 975-986
    • Luk, K.C.1    Kehm, V.M.2    Zhang, B.3    O'Brien, P.4    Trojanowski, J.Q.5    Lee, V.M.6
  • 95
    • 36248965693 scopus 로고    scopus 로고
    • Role of different regions of 9-synuclein in the assembly of fibrils
    • Qin, Z.; Hu, D.; Han, S.; Hong, D.P.; Fink, A.L. Role of different regions of 9-synuclein in the assembly of fibrils. Biochemistry 2007, 46, 13322-13330.
    • (2007) Biochemistry , vol.46 , pp. 13322-13330
    • Qin, Z.1    Hu, D.2    Han, S.3    Hong, D.P.4    Fink, A.L.5
  • 96
    • 84903441419 scopus 로고    scopus 로고
    • α-synuclein immunotherapy blocks uptake and template propagation of misfolded α-synuclein and neurodegeneration
    • Tran, H.T.; Chung, C.H.; Iba, M.; Zhang, B.; Trojanowski, J.Q.; Luk, K.C.; Lee, V.M.Y. α-synuclein immunotherapy blocks uptake and template propagation of misfolded α-synuclein and neurodegeneration. Cell Rep. 2014, 7, 2054-2065.
    • (2014) Cell Rep. , vol.7 , pp. 2054-2065
    • Tran, H.T.1    Chung, C.H.2    Iba, M.3    Zhang, B.4    Trojanowski, J.Q.5    Luk, K.C.6    Lee, V.M.Y.7
  • 97
    • 79955757052 scopus 로고    scopus 로고
    • Passive immunisation reduces behavioural and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease
    • Masliah, E.; Rockenstein, E.; Mante, M.; Crews, L.; Spencer, B.; Adame, A.; Patrick, C.; Trejo, M.; Ubhi, K.; Rohn, T.T.; et al. Passive immunisation reduces behavioural and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011, 6, e19338.
    • (2011) PLoS One , vol.6
    • Masliah, E.1    Rockenstein, E.2    Mante, M.3    Crews, L.4    Spencer, B.5    Adame, A.6    Patrick, C.7    Trejo, M.8    Ubhi, K.9    Rohn, T.T.10
  • 98
    • 0035815664 scopus 로고    scopus 로고
    • Evidence for a partially folded intermediate in alpha-synuclein fibril formation
    • Uversky, V.N.; Li, J.; Fink, A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 2001, 276, 10737-10744.
    • (2001) J. Biol. Chem. , vol.276 , pp. 10737-10744
    • Uversky, V.N.1    Li, J.2    Fink, A.L.3
  • 99
    • 84879419913 scopus 로고    scopus 로고
    • Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognise brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation
    • Fagerqvist, T.; Lindstrom, V.; Nordstrom, E.; Lord, A.; Tucker, S.M.E.; Su, X.; Sahlin, C.; Kasrayan, A.; Andersson, J.; Welander, H.; et al. Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognise brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation. J. Neurochem. 2013, 126, 131-144.
    • (2013) J. Neurochem. , vol.126 , pp. 131-144
    • Fagerqvist, T.1    Lindstrom, V.2    Nordstrom, E.3    Lord, A.4    Tucker, S.M.E.5    Su, X.6    Sahlin, C.7    Kasrayan, A.8    Andersson, J.9    Welander, H.10
  • 100
    • 66449097646 scopus 로고    scopus 로고
    • Detecting morphologically distinct oligomeric forms of α-synuclein
    • Emadi, S.; Kasturirangan, S.; Wang, M.S.; Schulz, P.; Sierks, M. Detecting morphologically distinct oligomeric forms of α-synuclein. J. Biol. Chem. 2009, 284, 11048-11058.
    • (2009) J. Biol. Chem. , vol.284 , pp. 11048-11058
    • Emadi, S.1    Kasturirangan, S.2    Wang, M.S.3    Schulz, P.4    Sierks, M.5
  • 104
    • 33846817163 scopus 로고    scopus 로고
    • Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity
    • Volles, M.J.; Lansbury, P.T., Jr. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J. Mol. Biol. 2007, 366, 1510-1522.
    • (2007) J. Mol. Biol. , vol.366 , pp. 1510-1522
    • Volles, M.J.1    Lansbury, P.T.2
  • 105
    • 77958449984 scopus 로고    scopus 로고
    • 1-Synuclein: Membrane interactions and toxicity in Parkinson's disease
    • Auluck, P.K.; Caraveo, G.; Lindquist, S. 1-Synuclein: membrane interactions and toxicity in Parkinson's disease. Ann. Rev. Cell Develop. Biol. 2010, 26, 211-233.
    • (2010) Ann. Rev. Cell Develop. Biol. , vol.26 , pp. 211-233
    • Auluck, P.K.1    Caraveo, G.2    Lindquist, S.3
  • 106
    • 10344257196 scopus 로고    scopus 로고
    • A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein
    • Zhou, C.; Wmadi, S.; Sierks, M.R.; Messer, A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol. Ther. 2004, 10, 1023-1031.
    • (2004) Mol. Ther. , vol.10 , pp. 1023-1031
    • Zhou, C.1    Wmadi, S.2    Sierks, M.R.3    Messer, A.4
  • 107
    • 39649109675 scopus 로고    scopus 로고
    • An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity
    • Lynch, S.M.; Zhou, C.; Messer, A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J. Mol. Biol. 2008, 377, 136-147.
    • (2008) J. Mol. Biol. , vol.377 , pp. 136-147
    • Lynch, S.M.1    Zhou, C.2    Messer, A.3
  • 109
    • 84860692601 scopus 로고    scopus 로고
    • Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins
    • Butler, D.C.; McLear, J.A.; Messer, A. Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins. Prog. Neurobiol. 2012, 97, 190-204.
    • (2012) Prog. Neurobiol. , vol.97 , pp. 190-204
    • Butler, D.C.1    McLear, J.A.2    Messer, A.3
  • 110
    • 82555176538 scopus 로고    scopus 로고
    • A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition
    • Schiefner, A.; Chatwell, L.; Korner, J.; Neumaier, I.; Colby, D.W.; Volkmer, R.; Wittrup, K.D.; Skerra, A. A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition. J. Mol. Biol. 2011, 414, 337-355.
    • (2011) J. Mol. Biol. , vol.414 , pp. 337-355
    • Schiefner, A.1    Chatwell, L.2    Korner, J.3    Neumaier, I.4    Colby, D.W.5    Volkmer, R.6    Wittrup, K.D.7    Skerra, A.8
  • 111
    • 54049111928 scopus 로고    scopus 로고
    • Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity
    • Southwell, A.L.; Khoshnan, A.; Dunn, D.E.; Bugg, C.W.; Lo, D.C.; Patterson, P.H. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J. Neurosc. 2008, 28, 9013-9020.
    • (2008) J. Neurosc. , vol.28 , pp. 9013-9020
    • Southwell, A.L.1    Khoshnan, A.2    Dunn, D.E.3    Bugg, C.W.4    Lo, D.C.5    Patterson, P.H.6
  • 113
    • 17544377783 scopus 로고    scopus 로고
    • A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease
    • Miller, T.W.; Zhou, C.; Gines, S.; MacDonald, M.E.; Mazarakis, N.D.; Bates, G.P.; Huston, J.S.; Messer, A. A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiol. Dis. 2005, 19, 47-56.
    • (2005) Neurobiol. Dis. , vol.19 , pp. 47-56
    • Miller, T.W.1    Zhou, C.2    Gines, S.3    McDonald, M.E.4    Mazarakis, N.D.5    Bates, G.P.6    Huston, J.S.7    Messer, A.8
  • 114
    • 84055182535 scopus 로고    scopus 로고
    • Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments
    • Butler, D.C.; Messer, A. Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One 2011, 6, e29199.
    • (2011) PLoS One , vol.6
    • Butler, D.C.1    Messer, A.2
  • 115
    • 0037154165 scopus 로고    scopus 로고
    • Effects of intracellular expression of antihuntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity
    • Khoshnan, A.; Ko, J.; Patterson, P.H. Effects of intracellular expression of antihuntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. USA 2002, 99, 1002-1007.
    • (2002) Proc. Natl. Acad. Sci. USA , vol.99 , pp. 1002-1007
    • Khoshnan, A.1    Ko, J.2    Patterson, P.H.3
  • 116
    • 62949091373 scopus 로고    scopus 로고
    • Autophagy: A lysosomal degradation pathway with a central role in health and disease
    • Eskelinen, E.; Saftig, P. Autophagy: A lysosomal degradation pathway with a central role in health and disease. Biochim. Biophys. Acta 2009, 1793, 664-673.
    • (2009) Biochim. Biophys. Acta , vol.1793 , pp. 664-673
    • Eskelinen, E.1    Saftig, P.2
  • 120
    • 84892960113 scopus 로고    scopus 로고
    • Probing the N-terminal β-sheet conversion in the crystal structure of the human prion protein bound to a nanobody
    • Abskharon, R.N.N.; Giachin, G.; Wohlkonig, A.; Soror. S.H.; Pardon, E.; Legname. G.; Steyaert, J. Probing the N-terminal β-sheet conversion in the crystal structure of the human prion protein bound to a nanobody. J. Am. Chem. Soc. 2014, 136, 937-944.
    • (2014) J. Am. Chem. Soc. , vol.136 , pp. 937-944
    • Abskharon, R.N.N.1    Giachin, G.2    Wohlkonig, A.3    Soror, S.H.4    Pardon, E.5    Legname, G.6    Steyaert, J.7
  • 122
    • 84908252425 scopus 로고    scopus 로고
    • Prion protein-specific antibodies-development, modes of action and therapeutics applications
    • Rovis, T.L.; Legname, G. Prion protein-specific antibodies-development, modes of action and therapeutics applications. Viruses 2014, 6, 3719-3737.
    • (2014) Viruses , vol.6 , pp. 3719-3737
    • Rovis, T.L.1    Legname, G.2
  • 125
    • 39849085645 scopus 로고    scopus 로고
    • CNS delivery of vectored prion-specific single-chain antibodies delays disease onset
    • Wuertzer, C.A.; Sullivan, M.A.; Qiu, X.; Federoff, H.J. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol. Ther. 2008, 16, 481-486.
    • (2008) Mol. Ther. , vol.16 , pp. 481-486
    • Wuertzer, C.A.1    Sullivan, M.A.2    Qiu, X.3    Federoff, H.J.4
  • 126
    • 84884241359 scopus 로고    scopus 로고
    • Gene-based antibody strategies for prion diseases
    • Cardinale, A.; Biocca, S. Gene-based antibody strategies for prion diseases. Int. J. Cell Biol. 2013, 2013, 710406.
    • (2013) Int. J. Cell Biol. , vol.2013
    • Cardinale, A.1    Biocca, S.2
  • 127
    • 84873085590 scopus 로고    scopus 로고
    • Recombinant single-chain antibody with the trojan peptide penetratin positioned in the linker region enables cargo transfer across the blood-brain barrier
    • Skrlj, N.; Drevensek, G.; Hudoklin, S.; Romih, R.; Curin Serbec, V.; Dolinar, M. Recombinant single-chain antibody with the trojan peptide penetratin positioned in the linker region enables cargo transfer across the blood-brain barrier. Appl. Biochem. Biotechnol. 2013, 169, 159-169.
    • (2013) Appl. Biochem. Biotechnol. , vol.169 , pp. 159-169
    • Skrlj, N.1    Drevensek, G.2    Hudoklin, S.3    Romih, R.4    Curin Serbec, V.5    Dolinar, M.6
  • 128
    • 84879968745 scopus 로고    scopus 로고
    • Developing therapeutic antibodies for neurodegenerative disease
    • Joy, Y.Y.; Watts, R.J. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 2013, 10, 459-472.
    • (2013) Neurotherapeutics , vol.10 , pp. 459-472
    • Joy, Y.Y.1    Watts, R.J.2
  • 129
    • 84863209627 scopus 로고    scopus 로고
    • Antibody-enabled small molecule drug discovery
    • Lawson, A.D.G. Antibody-enabled small molecule drug discovery. Nat. Rev. Drug Discov. 2012, 11, 519-525.
    • (2012) Nat. Rev. Drug Discov. , vol.11 , pp. 519-525
    • Lawson, A.D.G.1
  • 130
    • 67649805281 scopus 로고    scopus 로고
    • Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions
    • Kokjohn, T.A.; Roher, E.A. Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions. Alzheimer's Dement. 2009, 5, 340-347.
    • (2009) Alzheimer's Dement. , vol.5 , pp. 340-347
    • Kokjohn, T.A.1    Roher, E.A.2
  • 131
    • 35348932113 scopus 로고    scopus 로고
    • Transgenic animal models of neurodegenerative diseases and their application to treatment development
    • Rockenstein, E.; Crews, L.; Masliah, E. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv. Drug Deliv. Rev. 2007, 59, 1093-1102.
    • (2007) Adv. Drug Deliv. Rev. , vol.59 , pp. 1093-1102
    • Rockenstein, E.1    Crews, L.2    Masliah, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.